{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}],"title":"Number of participants with Grade 0-1 GVHD"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"}],"title":"Number of participants with Grade 2 GVHD"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}],"title":"Number of participants with Grade 3 GVHD"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"8"}],"units":"Participants"}],"description":"The severity of acute GVHD is measured based on Graft-vs-Host Disease:\n\nSeverity of GVHD Grade I +1 to +2 skin rash No gut or liver involvement\n\nGrade II +3 skin rash or\n\n* 1 gastrointestinal involvement and/or +1 liver involvement\n\nGrade III +2 to +4 gastrointestinal involvement and/or\n\n* 2 to +4 liver involvement with or without a rash\n\nGrade IV Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death","groups":[{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Dose Level 1: 12 Gy Iodine-131 + BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG001","title":"Dose Level 7: 22 Gy Iodine-131 + BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG002","title":"Dose Level 8: 24 Gy Iodine-131 + BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG003","title":"Dose Level 9: 26 Gy Iodine-131 + BC8 Monoclonal Antibody"},{"description":"RADIOIMMUNOTHERAPY: Patients receive therapeutic iodine I 131 monoclonal antibody BC8 IV on day -12.\n\nCONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo TBI on day 0.\n\nTRANSPLANTATION: After completion of TBI, patients undergo allogeneic PBSC transplant on day 0.\n\nIMMUNOSUPPRESSION: Patients with a matched related donor receive cyclosporine IV or PO BID on days -3 to 56 followed by a taper to day 180 in the absence of graft-versus-host disease. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO 2 BID on days 0 to 27. Patients with a matched unrelated donor receive cyclosporine IV or PO BID on days -3 to 100 followed by a taper to day 180. Beginning 4-6 hours after PBSC transplant, these patients also receive mycophenolate mofetil PO TID on days 0 to 40 followed by a taper to day 96.\n\niodine I 131 monoclonal antibody BC8: Given IV\n\nfludarabine phosphate: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nallogeneic hematopoietic stem cell transplantation: Undergo PBSC transplantation\n\nperipheral blood stem cell transplantation: Undergo PBSC transplantation\n\ncyclosporine: Given IV or PO\n\nmycophenolate mofetil: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG004","title":"Dose Level 10: 28 Gy Iodine-131 + BC8 Monoclonal Antibody"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Study participants that completed study treatment","reportingStatus":"POSTED","timeFrame":"100 days after transplant","title":"Severity of Acute GVHD in Patients Who Completed the Study Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}